Cox-2 Inhibitors Current Events | Cox-2 Inhibitors News | 6
|
| Page
6 of
20 |
396 Results |
|
|
|
Sort By:
Page Views | Date |
Cancer therapy: A role for MAPK inhibitors combined with mTORC1 inhibitors
Nearly a decade ago, while it was being tested as an immunosuppressive agent to prevent organ rejection in transplant patients, the drug rapamycin was also discovered to have anti-tumor properties. Since then, several rapamycin analogs known as mTOR (mammalian target of rapamycin) inhibitors have been tested in clinical trials for the treatment of... view more... (2008-08-22)
Clinical trial to test stem cell approach for children with brain injury
A unique clinical trial will gauge the safety and potential of treating children suffering traumatic brain injury with stem cells derived from their own bone marrow starting early next year. view more (2005-12-21)
EU invests 10.7 million Euro on EICOSANOX-a top-ranking project led from Karolinska Institutet
A decision has now been taken on the grant that the EU's Sixth Framework Programme is to provide for EICOSANOX, a major research project coordinated by Karolinska Institutet's Professor Jesper Z. Haeggström. The project, which ranked highest in its category, is an Integrated Project (IP) and is to be allocated research funding of 10.7 million... view more... (2005-02-13)
Similar outcomes for patients with ACS treated with different anticoagulant regimens
Patients with acute coronary syndromes such as unstable angina who were undergoing an invasive treatment and received one of three anticoagulant regimens did not have significant differences in the rates of ischemia or death after one year. view more (2007-12-05)
Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
UCLA scientists, along with collaborators from Purdue University, have demonstrated that HIV protease inhibitors - crucial drugs for HIV treatment - block a cellular enzyme important for generating the structural scaffolding for the cell nucleus. view more (2007-07-17)
'Polypill' improves survival rates for heart disease sufferers, says University study
A 'polypill' made up of a combination of drugs could extend the lives of thousands of patients with coronary heart disease, say researchers at The University of Nottingham. view more (2005-05-09)
Heart failure patients at greatest risk of death least likely to receive appropriate medications
Even though certain medications such as ACE inhibitors reduce the risk of death for patients with heart failure, patients at greatest risk often are not prescribed these medications. view more (2005-09-14)
Groundbreaking Canadian asthma study
A new report published in the prestigious New England Journal of Medicine (NEJM) shows that patients treated with bronchial thermoplasty, the first non-drug treatment for asthma, demonstrated an overall improvement in asthma control. view more (2007-03-29)
Drug combo may reduce protease inhibitor-related hardening of the arteries
Physiologists may have found a way to decrease the risk of hardening of the arteries that accompanies the long-term use of protease inhibitors, a class of drugs that has emerged as the most effective treatment against HIV and AIDS. view more (2006-09-05)
Tumors stopped from spreading to new sites
For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. view more (2007-04-06)
Novel approach may protect against heart attack injury
Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. view more (2008-07-11)
Blood pressure medication to treat multiple sclerosis?
Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer... view more... (2009-08-19)
Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found (http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001). view more (2009-01-29)
Time to lift the geoengineering taboo
Hot on the heels of the Royal Society's Geoengineering the Climate report, September's Physics World contains feature comment from UK experts stressing the need to start taking geoengineering - deliberate interventions in the climate system to counteract man-made global warming - more seriously. view more (2009-09-01)
Study suggests some drug resistance to influenza B medications
Use of certain common antiviral drugs during a recent influenza B epidemic in Japan showed the development of viruses with partial resistance to the drugs, according to a study in the April 4 issue of JAMA. view more (2007-04-04)
MNI researchers find a new role for mitochondria in cellular copper regulation
Copper is an essential part of our lives. From copper pipes and wires - to important copper-containing proteins in the body, copper is necessary for healthy growth and neurological development. view more (2007-05-02)
Diabetes drugs of the future
COMMON blood-pressure drugs that help prevent the life-threatening complications of diabetes may do so by slowing the accelerated ageing from which diabetics suffer. The discovery could one day lead to drugs that delay some of the symptoms of ageing in everyone. People with diabetes tend to age rapidly, particularly if they have type 1 diabetes,... view more... (2002-10-02)
Abacavir Could Play Important Future Role In Treatment Of Children With HIV-1 (p 733)
Results of the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial, published in this week's issue of THE LANCET, suggest an important future role for the drug abacavir in the treatment of children with HIV-1. Antiretroviral HIV-1 drug treatment for adults in more-developed countries usually involves combination therapy with two... view more... (2002-02-28)
Meta-analyses of global trials finds in favor of aromatase inhibitors
Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. view more (2008-12-12)
Curacyte awarded a EUR1.2M grant to fund development of Factor Xa inhibitors
Curacyte AG, a Munich-based drug development company, has announced that its wholly owned subsidiary, Curacyte Chemistry GmbH based in Jena, has been awarded a EUR1.2M R&D grant from the German State of Thuringia's Corporate Technology Development Program. The grant will fund the lead optimization and pre-clinical development of the Company's... view more... (2003-10-29)
|
|
| Page
6 of
20 |
396 Results |
|
|
|
Sort By:
Page Views | Date |
|
